Brief: Seres Therapeutics Q3 EPS USD 0.58
13/11/2024 12:00
Nov 13 (Reuters) - Seres Therapeutics Q3 operating expenses USD 29.17 million. * Q3 operating income USD -29.17 million * Q3 net income USD 88.776 million
Recent news on Seres Therapeutics
See all newsChinese automakers make tech-led pitch for Europe's premium car market
Brief: Seres Therapeutics - May Offer Up To $300 Million Of Securities
Seres Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary
Seres Therapeutics Q2 net income turns positive on VOWST sale gain
Brief: Seres Therapeutics Q2 EPS USD 0.47